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Safety and efficacy of the fully human
anti-CD20 monoclonal antibody, ofatu-
mumab, was analyzed in a multicenter
dose-escalating study including 33 pa-
tients with relapsed or refractory chronic
lymphocytic leukemia. Three cohorts of
3 (A), 3 (B), and 27 (C) patients received
4, once weekly, infusions of ofatumumab
at the following doses: (A) one 100 mg
and three 500 mg; (B) one 300 mg and
three 1000 mg; (C) one 500 mg and three
2000 mg. Sixty-seven percent of the pa-
tients were Binet stage B, and the median
number of previous treatments was
3. The maximum tolerated dose was not
reached. The majority of related adverse
events occurred at first infusion, and the
number of adverse events decreased at
each subsequent infusion. Seventeen
(51%) of 33 patients experienced infec-
tions, 88% of them of grade 1-2. One
event of interstitial pneumonia was fatal;
all other cases resolved within one month.
The response rate of cohort C was 50%
(13/26), one patient having a nodular par-
tial remission and 12 patients partial re-
mission. In conclusion, ofatumumab was
found to be well tolerated in patients with
chronic lymphocytic leukemia (CLL) in
doses up to 2000 mg. Preliminary data on
safety and objective response are encourag-
ing and support further studies on the role
of ofatumumab in CLL patients. This trial
was registered at www.clinicaltrials.gov
as no. NCT00093314. (Blood. 2008;111:
1094-1100)
© 2008 by The American Society of Hematology
Introduction
The clinical course of chronic lymphocytic leukemia (CLL) is
often indolent, but the disease remains incurable.1,2 Symptomatic
patients have a survival between 1 and 7 years, even with the best
therapeutic approaches.2,3 Initial therapeutic options for patients
with stage B or C are chlorambucil, fludarabine alone (F regimen),
fludarabine combined with cyclophosphamide (FC regimen), or
fludarabine with rituximab (FC R regimen).3-5 Several phase 2
studies have shown an improvement in response rates and progres-
sion-free survival when chemotherapy is combined with ritux-
imab.67 However, all patients eventually experienced disease
progression, and there are then limited therapeutic options, espe-
cially for patients who are refractory to fludarabine.8
Two monoclonal antibodies (MAbs) have been widely used for
progressing patients: rituximab and alemtuzumab. Rituximab alone
is not widely used because of its low response rate in pretreated and
untreated patients.9 Alemtuzumab yields good response rates but is
also associated with high toxicity, particularly opportunistic infec-
tions.10,11 Although a number of combination regimens were
evaluated for relapsed and refractory patients, at present no
regimen has been shown to be convincingly superior.
There is growing evidence that MAb therapeutic activity in vivo
is dependent upon complement activation and subsequent comple-
ment-dependent cytotoxicity (CDC).12,13 Effective CDC might be
dependent on the distance between the plasma membrane and the
constant parts of the sensitizing antibody.14 This would explain
why MAb directed at membrane proximal targets such as CD20
and CD52 are more effective than those targeted at more extended
yet equally expressed molecules such as CD45.15 Another property
that can substantially affect the ability of a MAb to induce potent
CDC is whether it is able to redistribute the target antigen into
Triton X-100–insoluble areas of the plasma membrane.16 Ritux-
imab and ofatumumab both target CD20 and show equivalent
performance in the Tx100 insolubility assay.16
Ofatumumab is a new fully human anti-CD20 MAb with higher
in vitro efficacy on CLL cells.16 Ofatumumab is able to lyse
rituximab-resistant Raji cells, which express low levels of CD20
and high levels of complement-regulatory proteins CD55 and
CD59. Ofatumumab can also lyse CD20 low-expressing CLL cells
in the presence of human plasma or unfractionated blood. It is
hypothesized that ofatumumab efficacy in these cases is due to a
slower off-rate and more stable CD20 binding in comparison with
rituximab.16 Ofatumumab targets a different epitope than rituximab
of the CD20 antigen and this may explain some of the difference
between rituximab and ofatumumab.17 Because of these properties,
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ofatumumab might be an effective treatment for relapsed or
refractory patients who have already been treated with rituximab.
We present here the safety and efficacy results of the first study of
ofatumumab in patients with relapsed or refractory CLL.
Methods
Patients
All patients had relapsing or refractory CLL with circulating lymphocyte
count more than 5 109/L (5000/L) and were 18 years or older with a life
expectancy greater than 3 months. Circulating lymphocytes in the screening
blood sample had to be CD5, CD20, and CD23. The main exclusion
criteria were significant acute or chronic comorbidity; treatment with
rituximab, alemtuzumab, or autologous stem-cell transplantation within the
last 6 months; and previous treatment with allogeneic stem cell transplanta-
tion. Patients with known positivity for hepatitis B virus (HBV), hepatitis C
virus (HCV), or human immunodeficiency virus (HIV) were excluded.
Furthermore, patients with Richter syndrome, platelet count lower than
75  109/L (75 000/L), neutrophil count lower than 1.5  109/L (1500/
L), creatinine level higher than 1.5 times the upper normal limit (UNL),
bilirubin level higher than 1.5 UNL, and transaminases or alkaline
phosphatases higher than 2.5 UNL were also excluded. The study was
performed in accordance with Good Clinical Practices and local regulatory
requirements. The study protocol was approved by the appropriate
national authorities and institutional review boards/ethics committees
of each participating institution (see affiliations list). Each patient gave
written informed consent in accordance with the Declaration of
Helsinki to participate.
Study design
This open-label phase 1/2 study was performed between September 2004
and April 2006. Twelve sites have included patients: Denmark (3 sites),
France (2 sites), the Netherlands (1 site), Poland (5 sites), and United States
(1 site). The primary objective was to evaluate the safety and efficacy of
ofatumumab in patients with refractory or relapsing CLL. Patients received
4 weekly infusions of ofatumumab at 3 different doses. The
3 patients in cohort A received a first infusion of 100 mg ofatumumab and
3 subsequent infusions of 500 mg. The 3 patients of cohort B received a first
infusion of 300 mg and 3 subsequent infusions of 1000 mg. And the
27 patients of cohort C received a first infusion of 500 mg and 3 subsequent
infusions of 2000 mg. Before each infusion, patients received 1 g oral
paracetamol (acetaminophen) 30 to 60 minutes prior to treatment and
intravenous antihistamine 30 minutes prior to treatment. Before the first and
second infusion, patients received intravenous glucocorticoid equivalent to
50 mg prednisolone 30 minutes prior to treatment. The intravenous
glucocorticoid dose was repeated before the third and fourth infusion for
patients who had an infusion-related adverse event grade 3 or more at the
previous infusion. Inclusion in cohorts B and C was done when the 3
patients in the previous cohort had received the 4 infusions and had
satisfactory safety evaluations after 1 week of follow-up. During the
treatment phase, the patients were followed for safety assessments, and
samples for efficacy measurements (flow cytometric analyses) and
pharmacokinetics were obtained. No infection prophylaxis was sched-
uled in the protocol.
In case of adverse events during infusion, the infusion rate was temporarily
decreased or halted according to the investigator’s judgment and the patients
were treated with best clinical practice. If the patient showed signs of cytokine
release syndrome with beginning signs of breathing difficulty, the infusion had to
be stopped immediately and the patient treated according to best clinical practice.
Whether to resume the infusion upon the patient’s complete recovery was to be
decided by the investigator. In case of very slow infusion rates due to
infusion-related adverse events, intravenous glucocorticoids equivalent to 50 mg
prednisolone could be given. Low infusion rates resulting in overnight stay at the
hospital were not considered a serious adverse event (SAE).
Safety assessments
Adverse events (AEs) were reported throughout the study period and
graded according to the National Cancer Institute (NCI) Common Terminol-
ogy Criteria for Adverse Events (CTCAE) version 3.0 (Bethesda, MD).
Related grade 3 AEs and serious AEs (SAEs) were followed until resolved
or stable. Biochemistry and hematology parameters were assessed from
blood samples on days 1, 3, 5, 22, and 25. Vital signs and electrocardiogram
(ECG) were monitored regularly. Flow cytometry at screening and at
week 4 was performed to analyze CD3-, CD4-, CD8-, CD16-,
and CD56-expressing cells to follow whether T-cell subpopulations
or natural killer (NK) cells were affected by treatment with ofatumumab.
The formation of human antihuman antibodies against ofatumumab
was assessed at baseline and at end of study by an enzyme-linked
immunosorbent assay.
Efficacy assessments
The primary efficacy variable was objective response over the period from
screening to week 19 and was reported according to the NCI-Working
Group 1988 and 1996 criteria as complete remission (CR), nodular partial
remission (nPR), partial remission (PR), progressive disease (PD), stable
disease (SD), and nonevaluable patients (NEs).18,19 Response was assessed
on the following parameters: (a) lymph node size measured as the sum of
the product of diameters (SPDs) of the largest palpable nodes in each of the
following sites: cervical, axillary, supraclavicular, inguinal, and femoral;
lymph nodes larger than 1 cm were included; (b) hepatomegaly and
splenomegaly were measured in centimeters under the costal margin;
(c) hemoglobin level, and platelet, lymphocyte, and neutrophil counts;
(d) unilateral bone marrow aspirate and biopsy were performed at week
19 or 27 for patients with blood lymphocyte count less than 4.5  109/L
(4500/L); (e) computed tomography (CT) scans of neck, thorax, abdomen,
and pelvis were performed before treatment and at week 19 or 27 depending
on the date of the clinical response. CT scans were used to confirm the
response in responding patients.
The secondary efficacy variables were overall tumor response up to
week 27; CLL cells (CD5CD20 and CD5CD19) and normal B-cell
(CD20CD5) levels in peripheral blood assessed by flow cytometry; time
to progression; duration of response; and time to next anti-CLL therapy.
Statistical analyses
Under the assumption that 50% of the patients would achieve an objective
response, a 2-sided 95% confidence interval using the large sample normal
approximation for the proportion of patients achieving an objective
response was 31% to 69%. The lower limit was therefore higher than 30%,
which was considered to be the lowest response level that was clinically
relevant. Based on this, 26 patients were planned for cohort C. However,
1 patient had already signed the informed consent and commenced
screening when the target of 26 patients was reached, and therefore a
total of 27 patients were included in the study. The efficacy analysis
was performed on all patients exposed to the study drug in group C (full
analysis population).
The primary efficacy end point was objective tumor response over the
period from screening to week 19. Overall tumor response was assessed on
data from physical examinations and evaluation of the peripheral blood and
bone marrow as defined by NCI-WG Guidelines in CLL.18,19 According to
these criteria, the response is required to last for a period of 2 months.
Therefore clinical response first obtained at week 11 or 19 had to be
confirmed at week 19 or 27, respectively. The number of patients achieving
objective tumor response over the period from screening to week 19 was
derived for cohort C and presented together with 95% confidence interval.
The confidence interval was derived for the full analysis population
(primary analysis) and for the per protocol population (secondary analysis).
Time to progression was defined as the number of days from day 0 to first
disease progression or death related to CLL. Response duration was defined
as number of days from first documentation of response (defined as CR,
nPR, or PR) to first disease progression. Time to next treatment was defined
as days from day 0 to the date when any other anti-CLL therapy is started.
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Results
Forty-two patients were screened, and 9 failed screening; thus,
33 patients took part in the study. Maximum tolerated dose was not
reached. Three patients were allocated to each of cohorts A and B
and 27 patients to cohort C. All patients completed treatment
except one patient in cohort C who was withdrawn after the first
infusion due to drug-related SAE.
The patient population is described in Table 1. Median age was
61 years, ranging from 27 to 82 years. Median time from diagnosis
of CLL to study was 6.3 years (range, 1.2-14 years), and median
time since latest CLL treatment was 0.8 years (range,
0.1-5.3 years). Median number of prior treatments was 3 (range,
1-9). Most patients had Rai stage I or II (39% and 45%,
respectively) or Binet stage A or B (21% and 67%, respectively)
at time of study entry.
Safety results
Of the 33 patients enrolled in the study, 32 received all 4 infusions.
One patient withdrew because of a SAE the day after the first
infusion (cytolytic hepatitis, grade 3). This patient, who also had
temporarily increased liver enzymes before enrollment, completely
recovered after 3 days. Twenty-seven patients reported 246 AEs of
which 92% were mild (grade 1-2) and only 19 AEs were grade 3 or
4 (Table 2). Ten of the AEs were serious (Table 3). Of all AEs, 61%
(150/246) were assessed as related to the treatment. The majority of
AEs, 138 (56%), were reported on an infusion day, and of these 84
(61%) were reported on the day of the first infusion. The
infusion-related events usually occurred within the first few hours
after starting the infusion with the most common symptoms being
transient rigors, pyrexia, fatigue, rash, and increased sweating.
Infusion-related AEs tended to decrease in number and in intensity
for subsequent infusion days (Figure 1).
Seventeen patients (51%) reported infections. The most fre-
quently observed infection was nasopharyngitis (8/25 infectious
AEs) with a median onset 139 days after first infusion (range,
10-354 days). All but one patient recovered within a month. The
majority of the infections were of grade 1 or 2, whereas 3 events
were grade 3: herpes zoster (SAE), nasopharyngitis, pneumonia
(SAE), and 1 was fatal (infectious interstitial lung disease). In
addition, another patient had a grade 2 event of sinusitis that was
reported as an SAE.
Hematologic toxicity was reported in 15% of patients (8 events
in 5 patients). Four of those AEs were considered related to the
treatment: 2 cases of neutropenia and 2 thrombocytopenias. The
2 neutropenias were grade 4 and reported as SAEs. The 2 patients
with thrombocytopenia had entered the study with medical histo-
ries of thrombocytopenia that aggravated to grade 3 during the
Table 1. Demographics and baseline characteristics
Parameters Median
Demography
Age, y (min-max) 61 (27-82)
Male, no. (%) 19 (58%)
White, no. (%) 33 (100%)
Disease characteristics (min-max)
Duration of CLL, y 6.3 (1.2-14)
Time from latest treatment, y 0.8 (0.1-5.3)
No. of previous treatments 3 (1-9)
Modified Rai stage at screening, no. (%)
0 1 (3)
I 13 (39)
II 15 (45)
III 1 (3)
IV 3 (9)
Modified Binet stage at screening, no. (%)
A 7 (21)
B 22 (67)
C 4 (12)
Constitutional symptoms, no. (%)
Extreme fatigue 2 (6)
Night sweats 5 (15)
Fever 0
Weight loss 0
Hematologic symptoms, no. (%)
Anemia, hemoglobin level less than 10 g/L 7 (21)
Neutropenia, neutrophil count less than 1.5109/L 0 (0)
Thrombocytopenia, platelet count less than 120109/L 9 (27)
Lymphocytes/109/L (min-max) 51.3 (8.2-227.2)
LDH level above normal value, no. (%) 7 (21)
Lymph nodes, no. (%)
None 5 (15)
More than 5 cm in diameter 4 (12)
SPD more than 50 cm² 4 (12)
Splenomegaly, no. (%)
No 22 (67)
More than 5 cm below diaphragm 2 (6)
Table 2. Summary of toxicity grades 3 and 4 according to the NCI
Common Terminology Criteria for Adverse Events (CTCAE) version
3.0
MedDRA System Organ Class preferred term
No. of patients
(%)
No. of
events
Total no. of subjects with grade 3 or 4 adverse events 10 (30) 18
Blood and lymphatic system disorders 4 (12) 7
Thrombocytopenia 3 (9) 4
Neutropenia 2 (6) 2
Anemia NOS 1 (3) 1
Infections and infestations 3 (9) 3
Herpes zoster 1 (3) 1
Nasopharyngitis 1 (3) 1
Pneumonia NOS 1 (3) 1
General disorders and administration site conditions 2 (6) 3
Pyrexia 2 (6) 2
Pain NOS 1 (3) 1
Nervous system disorders 2 (6) 2
Carotid artery stenosis 1 (3) 1
Dizziness 1 (3) 1
Cardiac disorders: angina pectoris 1 (3) 1
1 (3) 1
Hepatobiliary disorders: cytolytic hepatitis 1 (3) 1
1 (3) 1
Respiratory, thoracic, and mediastinal disorders: hypoxia 1 (3) 1
1 (3) 1
Table 3. Serious adverse events (SAEs) observed in the 3 cohorts
No. of patients, n33 No. of SAEs
Totals of subjects and events 9 10
Herpes zoster 1 1
Pneumonia 1 1
Sinusitis 1 1
Neutropenia 2 2
Hemolytic anemia 1 1
Angina pectoris 1 1
Cytolytic hepatitis 1 1
Carotid artery stenosis 1 1
Interstitial lung disease 1 1
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study. Three patients had recovered by the end of the reporting
period. One CTC grade 2 SAE of hemolytic anemia was reported in
a 50-year-old man who was hospitalized for transfusions. This
patient had a history of fludarabine-induced hemolytic anemia, and
the event was considered not related to study drug. For hemoglo-
bin, a modest downward shift within the normal range was
observed during treatment.
In total, 9 patients reported 10 SAEs (Table 2) during the
study, of which 5 were considered treatment related: herpes
zoster (1 patient), neutropenia (2 patients), interstitial lung disease
(1 patient), and cytolytic hepatitis (1 patient). The event of
infectious interstitial lung disease was fatal. The patient, an
82-year-old man, had previously had 4 lines of treatment for CLL
and had profound chronic hypogammaglobulinemia. He had
3 episodes of interstitial pneumonia the previous year. Although the
event was most likely caused by the underlying disease, a
contribution of the study drug could not be completely excluded.
The event of cytolytic hepatitis occurred in a 74-year-old male
patient who showed an increase in hepatic enzymes during routine
examination the day of first infusion. The patient had elevated liver
parameters before enrollment; he fully recovered from the event. In
addition, 2 events with fatal outcome were reported after the end of
the study. One patient who was withdrawn from treatment due to
disease progression and had started chemotherapy died of pneumo-
nia 4 months after the end of ofatumumab treatment. One patient
died of disease progression 11 months after final treatment. Both
events were considered unrelated to ofatumumab treatment.
Mean serum immunoglobulin A (IgA) and IgG remained stable,
within or slightly lower than the normal range. Mean serum IgM
tended to decrease to lower than normal during the study. Overall,
more than half of the patients did not show any change in terms of
T cells or NK cells. Human antihuman antibodies were not detected
in any patient.
Efficacy results
The primary efficacy variable, objective response over the period
from screening to week 19, is presented in Table 4. The remission
rate in cohort C was 50% (95% confidence interval [CI]: 30%-
70%). There were no complete remissions, but in cohort A 1 patient
reached a PR and in cohort C 1 patient had a nPR and 12 patients
had PR. One cohort C patient presenting with PR showed all
features of nPR, except that CT scanning identified residual
lymphadenopathy. In cohort C, 62% (16/26) obtained response as
evaluated by physical examination and peripheral blood 4 weeks
after commencing treatment. Three patients did not respond until
week 7 or 11. Not all of these responses were sustained, and at
week 19 the number of patients with sustained response was
limited to 9. Of the patients previously treated with rituximab (7),
alemtuzumab (6), and/or fludarabine (20), 7 responded to ofatu-
mumab treatment. Two patients maintained their response to week
27, while the remaining evaluable patients had progressive disease
by this time with a median progression-free survival of 106 days
but a median time to next treatment of 1 year.
Most patients in cohort C showed more than 50% decrease in
lymph node size from week 4. This shrinkage was sustained until
week 15 after which SPD gradually progressed. A subset of patients
demonstrated a sustained, reduced lymph node size until week 27,
the end of the reporting period. Lymph node size over time for
cohort C patients is presented in Figure 2.
Hematology parameters may reflect efficacy if they improve on
treatment. Of the 7 anemic patients (hemoglobin level  120 g/L
[12 g/dL]) at baseline, 6 had an improvement (1 in cohort B and 5
in cohort C). Of the 9 patients with thrombocytopenia at baseline, 8
improved on therapy (2 in cohort A, 1 in cohort B, and 5 in cohort
C). Lymphocyte, neutrophil, and platelet counts over time for
cohort C are presented in Table 5.
Posttreatment bone marrow examination was performed on
11 patients in cohort C. In the 8 patients who responded to
treatment, the median percentage of marrow lymphocytes was 78%
(range, 30%-90%) before treatment and 50% (range, 5%-75%)
after treatment. After treatment, 3 patients had less than 30%
Figure 1. Number of adverse events on each infusion day by treatment cohort.
Table 4. Primary end point: objective response from screening to
week 19
Cohort A,
n  3
Cohort B,
n  3
Cohort C,
n  27
Total,
n  33
Not evaluable 0 0 1 1
Objective response (%) 1 (33) 0 13 (50) 14 (44)
95% CI, % 1-91 — 30-70 29-67
— indicates not applicable.
Figure 2. Change from baseline in sum of products of greatest lymph node
diameters in cohort C.
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lymphocytes (5%, 10%, and 25%) but all had a nodular growth
pattern.
In cohort C, a median 55% reduction in malignant CD5CD19
B cells in peripheral blood was observed after the first infusion.
After the fourth infusion, the median percentage reduction from
baseline was 97% ranging from 15% to 100% (Figure 3). Observa-
tions were similar for CD5CD20 B cells. Normal B cells were
also depleted. For the majority patients, this depletion was sus-
tained until approximately week 24, after which the number of
B cells gradually rose.
Discussion
This study presents the results of ofatumumab, a fully human
anti-CD20 monoclonal antibody, in CLL patients and shows a
response (PR or nPR) in half of the patients treated in the phase
2 part. This is superior to the results obtained with rituximab in
the same setting even if it is very difficult to compare patients’
status and probability of response in different phase 1/2 studies.
Huhn et al obtained a response in 7 (25%) of the 28 treated
patients.20 Itala et al obtained a response in 8 (35%) of the 24
treated patients.21 Response rates increased to 58% with CR in
untreated patients with CLL.22 Response rates increased to 45%
with rituximab alone in relapsing patients when rituximab was
given 3 times a week.9 Similarly, O’Brien et al found a
correlation between dose and response in CLL patients treated
with rituximab alone: 22% for patients treated at 500 to
825 mg/m2, 43% for those treated at 1000 to 1500 mg/m2, and
75% for those treated at the highest dose of 2250 mg/m2.23
Median duration of response was short in all these studies,
except in the O’Brien et al study, ranging from 10 to 20 weeks in
patients treated with standard dose of rituximab but longer
(8 months) in patients receiving higher dose of rituximab. In our
series, median PFS was 15 weeks.
In vitro, compared with rituximab at the same concentration,
ofatumumab has a greater activity on CLL cells for CDC, and
this was related to a lower off-rate of the Ig from the cell
surface.16 Ofatumumab also targets a different epitope of the
CD20 molecule and this is also correlated to the CDC activity.17
So, there are several biologic reasons that may explain the
greater activity in patients on ofatumumab compared with
rituximab. However, the efficacy of rituximab was determined
on its use in thousands of patients and this relatively small
phase 1/2 study is not sufficient to definitively conclude that
ofatumumab is superior. Only 7 patients had previously received
rituximab, alone or in combination with chemotherapy, and 1 of
them reached a PR after ofatumumab.
These results showed a clear relationship between dose and
efficacy with only one responder among cohorts A and B and
few improvements in lymphocytes counts or SPD in these
2 cohorts with lower dose. In another phase 1/2 study with
ofatumumab in patients with follicular lymphoma, the dose
effect tested between 300 mg and 1000 mg flat dose was not
evident as described for rituximab in follicular lymphoma
patients.24 Can we conclude that the higher efficacy of ofatu-
mumab in CLL patients compared with rituximab is related to
the higher dose of the antibody used? Only a comparison study
with rituximab will allow conclusions to be drawn, but the in
vitro data are clearly in favor of a superior efficacy of
ofatumumab in relapsing CLL patients.
Table 5. Hemoglobin level, neutrophil count, and platelet count at screening, during treatment, and after treatment
Screening
Time from screening
Wk 1 Wk 2 Wk 3 Wk 4 Wk 7 Wk 11 Wk 15 Wk 19 Wk 23 Wk 27 Mo 9 Mo 12
Hemoglobin level, g/L
N 33 33 32 32 32 30 30 27 23 20 18 7 8
Mean 131 122.5 123 123 125 129 131 135 138 141 137 145 140
Median 135 123 122 121 124 130 133 135 138 139 132 147 140
Minimum 96 79 100 91 94 109 100 107 108 113 106 121 122
Maximum 154 151 146 146 159 150 162 168 174 169 165 175 156
Neutrophil count,109/L
N 33 33 32 32 32 30 30 27 23 20 18 7 8
Mean 16.12 4.63 3.89 4.04 3.43 3.43 3.62 6.27 4.47 3.97 4.11 4.51 4.34
Median 6.20 3.50 3.15 2.80 2.95 3.15 2.90 4.00 3.90 3.65 3.50 4.20 3.95
Minimum 1.60 0.00 0.60 0.10 0.10 0.20 0.80 1.60 1.10 1.70 1.40 1.60 2.90
Maximum 147.1 19.30 15.20 33.50 16.50 7.90 16.00 32.60 21.40 8.20 12.50 8.40 6.00
Platelet count, 109/L
N 33 33 32 31 32 30 30 27 23 20 18 7 8
Mean 152 158 168 168 179 182 177 172 179 181 170 185 180
Median 145 163 170 155 171 172 169 161 169 175 180 190 173
Minimum 69 48 41 75 84 68 49 50 47 104 45 142 132
Maximum 279 312 329 291 311 348 352 368 374 307 271 219 227
Figure 3. Leukemic B cells in peripheral blood in cohort C.
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Of the 33 patients enrolled in the trial, 32 received all
4 infusions. One patient was withdrawn from treatment after the
first infusion due to a grade 3 cytolytic hepatitis. Almost all
(92%) reported AEs were of CTC grade 1 or 2, and most were
observed during or just after the first infusion. Thus, these AEs
were not completely prevented by the use of premedication
regimen of paracetamol, antihistaminic, and glucocorticoids.
The most common infusion-related symptoms were transient
rigors, pyrexia, fatigue, rash, and increased sweating, which
probably resulted from the cytokine-release syndrome to be
expected with anti-CD20 treatment in CLL patients. Infusion-
related AEs reduced in number and intensity at each subsequent
infusion. This toxicity is similar to the one described with
rituximab in CLL patients.25
Infection due to immunosuppression is a concern when
depleting a patient’s normal B cells, and 51% of our patients had
at least one infection. The majority of the infections were of
grade 1 or grade 2 intensity, and nasopharyngitis was the most
frequently observed infectious event. One fatal event of infec-
tious interstitial lung disease was seen in a patient with
4 previous lines of treatment and profound chronic hypogamma-
globulinemia. The infection rate compares favorably with those
seen with other treatments such as fludarabine or alemtuzumab
in CLL patients.11,26,27 Cohort C mean serum IgA and IgG
remained stable despite the long-lasting reduction in the number
of peripheral CD20 B cells. Mean serum IgM level tended to
decrease lower than normal during the study, which is expected
with long-lasting depletion of normal B cells.28 T-cell counts
(CD3, CD4CD8, or CD4CD8) and NK cells remained
within normal ranges for all patients.
There were 8 events (3% of total) of hematologic toxicity. A
grade 2 hemolytic anemia occurred in a patient with a known
fludarabine-induced hemolytic anemia. Worsening of thrombo-
cytopenia was observed in 4 events in 3 patients who had a
medical history of thrombocytopenia. One of these patients also
had neutropenia (SAE) and anemia. One additional SAE of
neutropenia was recorded. These cytopenias are common in
patients with CLL, and a relationship with ofatumumab is not
certain. However, such cytopenias have been described with
rituximab in lymphoma patients; their mechanisms are not
completely understood.29 Flow cytometry results showed that
ofatumumab did result in the rapid and prolonged depletion of
circulating normal B lymphocytes in all patients. Serial evalua-
tion demonstrated that recovery to normal levels was not
observed until 5 to 6 months after completion of therapy, and in
a subset of patients the depletion was sustained until the end of
the study period, month 12. These results are similar to what was
described with rituximab.25
In the present study, ofatumumab, a fully human anti-CD20
monoclonal antibody, was found to be well tolerated in patients
with CLL in doses up to 2000 mg. Preliminary data on objective
response are encouraging and support further studies on the role of
ofatumumab in CLL patients.
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